A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Rabanal, Francesc ^a   Grau Campistany, Ariadna ^a   Vila Farrés, Xavier ^b   Gonzalez Linares, Javier ^c   Borràs, Miquel ^c   Vila, Jordi ^b   Manresa, Angeles ^a   Cajal, Yolanda ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c Barcelona Science Park   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CYCLOPEPTIDE; LIPOPEPTIDE;

AMINO ACID SEQUENCE; ANIMAL; BACTERIAL INFECTIONS; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DOG; DRUG EFFECTS; FIBROBLAST; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IC50; MDCK CELL LINE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOUSE; MULTIDRUG RESISTANCE; ULTRASTRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL INFECTIONS; DISEASE MODELS, ANIMAL; DOGS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FIBROBLASTS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INHIBITORY CONCENTRATION 50; LIPOPEPTIDES; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC;

EID: 84930679179     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10558     Document Type: Article

References (52)

1. Morel, C. M., & Mossialos, E. Stoking the antibiotic pipeline. British Med. J. 340, 1115-1118 (2010).
2. Cooper, M. A., & Shlaes, D. Fix the antibiotic pipeline. Nature 472, 32 (2011).
3. Butler, M. S., Blaskovich, M. A., & Cooper M. A. Antibiotics in the clinical pipeline in 2013. J. Antibiotics 66, 571-591 (2013).
4. Boucher, H. W. et al. Infectious Diseases Society of America. 10× '20 Progress-Development of new drugs active against gramnegative bacilli: an update from the infectious diseases society of America. Clin. Infect. Dis. 56, 1685-1694 (2013).
5. Guidos R. J., Infectious Diseases Society of America. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 52, S397-S428 (2011).
6. Mossialos, E. et al. Policies and Incentives for Promoting Innovation in Antibiotic Research. (2009) Available at: http://www.lse. ac.uk/LSEHealthAndSocialCare/impacts/LSEHealthNews/News%20Attachments/Policies%20and%20incentives%20report.pdf. (Date of access: 04/02/2015
7. CDC, Centre for Disease Control and Prevention, Threat report 2013. (2014) Available at: http://www.cdc.gov/drugresistance/threat-report-2013 (Date of access: 04/02/2015).
8. Smith, R., & Coast, J. The true cost of antimicrobial resistance. British Med. J. 346, f1430 (2013).
9. Walsh, C. T., & Wencewicz, T. A. Prospects for new antibiotics: a molecule-centered perspective. J. Antibiotics 67, 7-22 (2014).
10. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance 2014. (2014) Available at: http://apps.who. int/iris/bitstream/10665/112642/1/9789241564748eng.pdf (Date of access: 24/02/2015).
11. Woolhouse, M., & Farrar J. An intergovernmental panel on antimicrobial resistance. Nature 509, 555-557 (2014).
12. Editorial, A three-step plan for antibiotics, Nature 509, 533 (2014).
13. Gilbert D. N. et al. The 10x20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50, 1081-1083 (2010).
14. Reardon, S. Antibiotic resistance sweeping developing world. Nature 509, 141-142 (2014).
15. Rex J. H. ND4BB: addressing the antimicrobial resistance crisis. Nature Rev. Microbiol. 12, 231-232 (2014).
16. Viñas, M., Rabanal, F., Benz, R., Vinuesa, T., & Fusté, E. in Antimicrobial compounds: current strategies and new alternatives (eds Villa, T. G., & Veiga-Crespo, P.) Ch. 10, 269-284 (Springer Verlag GmbH, 2014).
17. Fjell, C. D., Hiss, J. A., Hancock, R. E. W., & Schneider, G. Designing antimicrobial peptides: form follows function. Naure. Rev. Drug Discov. 11, 37-51 (2012).
18. Pasupuleti, M., Schmidtchen, A., & Malmsten, M. Antimicrobial peptides: key components of the innate immune system. Crit. Rev. Biotechnol. 32, 143-171 (2012).
19. Yeaman, M. R., & Yount, N. Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55, 27-55 (2003).
20. Yount, N. Y., & Yeaman, M. R. Emerging themes and therapeutic prospects for anti-infective peptides. Annu. Rev. Pharmacol. Toxicol. 52, 337-360 (2012).
21. Brogden, K. A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nature Rev. Microbiol. 3, 238-250 (2005).
22. Brogden, N. K., & Brogden, K. A. Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? Int. J. Antimicrob. Agents 38, 217-225 (2011).
23. Srinivas, N. et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327, 1010-1013 (2010).
24. Finlay, B. B., & Hancock, R. E. W. Can innate immunity be enhanced to treat microbial infections? Nat. Rev. Microbiol. 2, 497-504 (2004).
25. Hancock, R. E. W., & Scott, M. G., The role of antimicrobial peptides in animal defences. Proc. Natl. Acad. Sci. USA 97, 8856-8861 (2000).
26. Rathinakumar, R., Walkenhorst, W. F., & Wimley, W. C. Broad-spectrum antimicrobial peptides by rational combinatorial design and high-throughput screening: the importance of interfacial activity. J. Am. Chem. Soc. 131, 7609-7617 (2009).
27. Vaara, M. Novel derivatives of polymyxins. J. Antimicrob Chemother. 68, 1213-1219 (2013).
28. Rabanal, F., Cajal, Y., Garcia-Subirats, M., & Rodríguez M., inventors; University of Barcelona assignee. Peptide compounds that can be used as antibacterial agents. United States patent US2013053305. 2010, March 10th
29. Nederberg, F. et al. Biodegradable nanostructures with selective lysis of microbial membranes. Nature Chemistry 3, 409-414 (2011).
30. Hurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nature Rev. Microbiol. 9, 62-75 (2011).
31. Clark, D. P., Durrel, S., Malloy, W. L., & Zasloff, M. Ranalexin, a novel antimicrobial peptide from Bullfrog (Rana Catesbeiana) skin, structurally related to the antibacterial antibiotic polymyxin. J. Biol. Chem. 269, 10849-10855 (1994).
32. Rustici, A. et al. Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science 259, 361-364 (1993).
33. Abdelraouf, K., Jie, H., Ledesma, K. R., Hu, M., & Tam, V. H. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob. Agents Chemother. 56, 5724-5727(2012).
34. Abdelraouf, K., Chang, K.-T., Yin, T., Hu, M., & Tam, V. H. Uptake of polymyxin B into renal cells. Antimicrob. Agents Chemother. 58, 4200-4202 (2014).
35. Yang, J. J., Kularatne, S. A., Chen, X., Low, P. S., & Wang, E. Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys. Mol. Pharm. 9, 310-317 (2012).
36. Yang, J. J., Chen, H., Vlahov, I. R., Cheng, J.-X., & Low, P. S. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging, Proc. Natl. Acad. Sci. USA 103, 13872-13877 (2006).
37. Geng, Q., Sun, X., Gong, T., & Zhang, Z.-R. Peptide-drug conjugate linked via a disulfide bond for kidney targeted drug delivery. Bioconjugate Chem. 23, 1200-1210 (2012).
38. Velkov, T., Thompson, P. E., Nation, R. L., & Li, J. Structure-Activity relationships of polymyxin antibiotics. J. Med. Chem. 53, 1898-1916 (2010
39. Chihara, S., Yahata, M., Tobita, T., & Koyama, Y. Chemical synthesis, isolation and characterization of ?-N-fattyacyl colistin nonapeptide with special reference to the correlation between antimicrobial activity and carbon number of fatty acyl moiety. Agric. Biol. Chem. 38, 521-529 (1974).
40. Velkov, T. et al. Teaching 'Old' Polymyxins New Tricks: New-Generation Lipopeptides Targeting Gram-Negative 'Superbugs'. ACS Chem. Biol. 9, 1172-1177 (2014).
41. Magee T. V. et al. Discovery of Dap-3 polymyxin analogues for the treatment of multi-drug-resistant gram-negative nosocomial infections. J Med Chem. 56, 5079-5093 (2013).
42. Solé, M. et al. First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob. Agents Chemother. 55, 4402-4404 (2011).
43. Alvarez-Barrientos, A., Arroyo, J., Canton, R., Nombela, C., & Sanchez-Perez, M. Applications of flow cytometry to clinical microbiology. Clinical Microbiology Reviews 13, 167-195 (2000).
44. Comas, J., & Vives-Rego, J. Assessment of the effects of gramicidin, formaldehyde, and surfactants on Escherichia coli by flow cytometry using nucleic acid and membrane potential dyes. Cytometry 29, 58-64 (1997).
45. Mogi, T. et al. Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate:quinone oxidoreductase from Gram-positive bacterium Mycobacterium smegmatis. J. Biochem. 146, 491-499 (2009).
46. Deris, Z. Z. et al. A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADHquinone oxidoreductase activity. J Antibiot. (Tokyo) 67, 147-151 (2014).
47. Friedrich, C. L., Moyles, D., Beveridge, T. J., & Hancock R. E. W. Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria. Antimicrob. Agents Chemother. 44, 2086-2092 (2000).
48. Santhana R. L. et al. Mesosomes are a definite event in antibiotic-treated Staphylococcus aureus ATCC 25923. Tropical Biomedicine 24, 105-109 (2007).
49. Clausell, A. et al. Gram negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J. Phys. Chem. B 111, 551-556 (2007).
50. Clausell, A., Rabanal, F., Garcia-Subirats, M., Alsina, M. A., & Cajal, Y. Membrane association and contact formation by a synthetic analogue of polymyxin B and its fluorescent derivatives. J Phys Chem B 110, 4465-4471 (2006).
51. Jorgensen, J. H., & Turnidge, J. D. Antibacterial susceptibility test: dilutions and diffusion methods in Manual of Clinical Microbiology (eds Murray, P. R., Baron, E. J., Jorgensen, J. H., Pfaller, M. A., & Yorken, R. H.) pp 1108 (ASM Press Washington DC, 2003).
52. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63 (1983).